Beaten up share price offers an opportunity
06/06/25 -"After incorporating our 2027 projections with double-digit top-line growth due to the upcoming product launches, we have reduced our long-term sales and EBITDA growth estimates to 6% (7% previously). ..."
Pages
52
Language
English
Published on
06/06/25
You may also be interested by these reports :
06/06/25
While a more cautious approach to our estimates has resulted in c.11% reduction in the target price, we still see Novo as a good investment ...
06/06/25
After incorporating our 2027 projections with double-digit top-line growth due to the upcoming product launches, we have reduced our long-term sales ...
02/06/25
We have updated our estimates with the latest figures. The EPS has improved due to lower-than-expected R&D costs. This improvement is supported by ...
01/06/25
CureVac has repositioned itself as an early-stage biotech company following the out-licensing of its infectious disease portfolio to GSK. The deal ...